安罗替尼联合热化疗用于广泛期小细胞肺癌二线治疗的有效性及安全性

Effectiveness and safety of anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with extensive-stage small cell lung cancer

目的 观察安罗替尼联合热化疗用于广泛期小细胞肺癌(extensive-stage small cell lung cancer,ES-SCLC)患者二线治疗的有效性及安全性。方法 选择2020年2月至2022年6月哈励逊国际和平医院收治的经一线治疗后复发的ES-SCLC患者40例,随机分为观察组及对照组,每组20例。对照组接受伊立替康热化疗,观察组在此基础上联合安罗替尼治疗(连服2周,停药1周),每3周为1个周期。比较两组疗效及不良反应。结果 化疗2个周期后,观察组实体肿瘤总有效率、肿瘤的疾病控制率、无进展生存期(progression-free survival,PFS)及总生存期(overall survival,OS)均高于对照组(P <0.05),观察组血清癌胚抗原、糖类抗原125、细胞角蛋白19片段抗原21-1、胃泌素释放肽前体及神经元特异性烯醇化酶均高于对照组(P <0.05)。两组化疗期间不良反应比较,差异无统计学意义(P> 0.05)。观察组血清血管内皮生长因子和血管生成素2均高于对照组(P <0.05)。结论 安罗替尼联合热化疗用于ES-SCLC患者的二线治疗,可提高近期疗效,降低血清肿瘤标志物水平,抑制肿瘤新生血管生成,延长PFS及OS,安全可靠。

Objective To investigate the effectiveness and safety of anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with extensive-stage small cell lung cancer(ES-SCLC).Methods A total of 40 patients with ES-SCLC who had relapsed after the first-line treatment admitted to Harrison international peace hospital from February 2020 to June 2022 were selected and randomly divided into the observation group and control group,20 cases in each group.The patients in the control group received hyperthermia chemotherapy with irinotecan and the patients in the observation group were treated with anlotinib based on the control group(took it for 2 weeks and stopped for 1 week).Every 3 weeks was a cycle.The efficacy and adverse reactions of the two groups were compared.Results After 2 cycles of chemotherapy,total effective rate for solid tumors,disease control rate of tumors,progression-free survival(PFS) and overall survival(OS) of the observation group were higher than those of the control group(P<0.05).The serum levels of carcinoembryonic antigen,carbohydrate antigen 125,cytokeratin 19 fragment antigen 21-1,pro-gastrin-releasing peptide,neuron-specific enolase of the observation group were higher than those of the control group(P<0.05).There was no significant difference in the occurrence of adverse reactions between the two groups during chemotherapy(P>0.05).The serum levels of vascular endothelial growth factor and angiopoietin-2 of the observation group were higher than those of the control group(P<0.05).Conclusion Anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with ES-SCLC can improve the short-term efficacy,reduce the level of serum tumor markers,inhibit tumor angiogenesis,prolong PFS and OS,and it is safe and reliable.